Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Feldman

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Biological Psychiatry|September 21, 2002
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's diseaseAlan Breier, Virginia K Sutton, Peter D Feldman, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 19, 2007
CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHDPaula T Trzepacz, David W Williams, Peter D Feldman, et al.
Psychopharmacology|November 10, 2006
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial dataJoseph Biederman, Thomas J Spencer, Jeffrey H Newcorn, et al.
Schizophrenia Research|October 25, 2011
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptomsVirginia L Stauffer, Guochen Song, Bruce J Kinon, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 26, 2006
Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorderChristopher J Kratochvil, Timothy E Wilens, Laurence L Greenhill, et al.
Neuropsychiatric Disease and Treatment|April 27, 2012
Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophreniaHaya Ascher-Svanum, Alan Jm Brnabic, Anthony H Lawson, et al.
The Journal of Clinical Psychiatry|November 25, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 yearsPeter D Feldman, Christopher J Kaiser, John S Kennedy, et al.
The Journal of Pediatrics|July 25, 2006
Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorderTimothy E Wilens, Jeffrey H Newcorn, Christopher J Kratochvil, et al.
Clinical Therapeutics|August 19, 2007
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy studyHumberto Quintana, Edward A Cherlin, David A Duesenberg, et al.
Journal of Affective Disorders|January 1, 2003
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cyclingTodd M Sanger, Mauricio Tohen, Eduard Vieta, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Biological Psychiatry|September 21, 2002
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's diseaseAlan Breier, Virginia K Sutton, Peter D Feldman, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 19, 2007
CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHDPaula T Trzepacz, David W Williams, Peter D Feldman, et al.
Psychopharmacology|November 10, 2006
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial dataJoseph Biederman, Thomas J Spencer, Jeffrey H Newcorn, et al.
Schizophrenia Research|October 25, 2011
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptomsVirginia L Stauffer, Guochen Song, Bruce J Kinon, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 26, 2006
Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorderChristopher J Kratochvil, Timothy E Wilens, Laurence L Greenhill, et al.
Neuropsychiatric Disease and Treatment|April 27, 2012
Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophreniaHaya Ascher-Svanum, Alan Jm Brnabic, Anthony H Lawson, et al.
The Journal of Clinical Psychiatry|November 25, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 yearsPeter D Feldman, Christopher J Kaiser, John S Kennedy, et al.
The Journal of Pediatrics|July 25, 2006
Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorderTimothy E Wilens, Jeffrey H Newcorn, Christopher J Kratochvil, et al.
Clinical Therapeutics|August 19, 2007
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy studyHumberto Quintana, Edward A Cherlin, David A Duesenberg, et al.
Journal of Affective Disorders|January 1, 2003
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cyclingTodd M Sanger, Mauricio Tohen, Eduard Vieta, et al.
Pageof 3